8-K: Glaukos Reports Record Q1 2025 Sales, Driven by iDose TR Adoption

Glaukos Corporation announced record net sales of $106.7 million for Q1 2025, a 25% increase year-over-year, driven by strong performance in glaucoma and corneal health segments.

Summary

• Glaukos Corporation reported its Q1 2025 financial results, highlighted by record net sales of $106.7 million.
• This represents a 25% increase compared to the same period in 2024, or 26% on a constant currency basis.
• Glaucoma net sales reached a record $88.1 million, up 31% year-over-year, with U.S. glaucoma sales at $59.1 million, a 41% increase.
• The company's gross margin was approximately 77%, with a non-GAAP gross margin of approximately 82%.
• Selling, general, and administrative expenses increased by 14% to $70.7 million.
• Research and development expenses increased by 5% to $32.4 million.
• The loss from operations was $20.7 million, an improvement from the $39.1 million loss in Q1 2024.
• Net loss was $18.1 million, or ($0.32) per diluted share, compared to a net loss of $40.8 million, or ($0.82) per diluted share, in Q1 2024.
• The company reaffirmed its 2025 net sales guidance of $475 million to $485 million.
• Glaukos ended the quarter with approximately $303.4 million in cash, cash equivalents, short-term investments, and restricted cash, with no debt.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with record sales, strong growth in key segments, and reaffirmed revenue guidance. While there are some negatives, such as the net loss, the overall tone is optimistic due to the company's growth trajectory and strategic advancements.

Positives

• Record net sales of $106.7 million in Q1 2025, a 25% increase year-over-year.
• Strong growth in U.S. Glaucoma net sales, up 41% year-over-year, driven by iDose TR.
• International Glaucoma net revenues increased by 15% year-over-year.
• Gross margin remained strong at approximately 77% (82% non-GAAP).
• Loss from operations improved significantly compared to the previous year.
• The company has a strong cash position with $303.4 million in cash and investments and no debt.
• FDA accepted for review of NDA submission for Epioxa (Epi-on) with a PDUFA date set for October 20, 2025.

Negatives

• The company experienced a net loss of $18.1 million, or ($0.32) per diluted share.
• Gross margin decreased slightly from 83% to 82% on a non-GAAP basis.
• Selling, general, and administrative expenses increased by 14% to $70.7 million.
• Cash and cash equivalents decreased from $323.6 million as of December 31, 2024, to $303.4 million as of March 31, 2025.

Risks

• The company's ability to successfully commercialize iDose TR therapy is subject to risks and uncertainties.
• General macroeconomic conditions, including foreign currency fluctuations and future health crises, could impact the business.
• The company depends on a limited number of third-party suppliers for components of its products.
• Securing and maintaining adequate coverage and reimbursement by third-party payors for procedures using Glaukos products is critical.
• The company faces risks related to compliance with federal, state, and foreign laws and regulations.
• The lengthy and expensive clinical trial process and the uncertainty of timing and outcomes from clinical trials pose risks.
• The company faces potential headwinds within its U.S. Corneal Health franchise associated with its entry into the Medicaid Drug Rebate Program (MDRP).
• The company acknowledges potential headwinds within its U.S. Glaucoma stent business associated with the final MIGS LCDs in 5 of the 7 MACs.

Future Outlook

Glaukos reaffirms its full-year 2025 global consolidated net sales guidance of $475 million to $485 million, considering potential contributions from iDose TR and iStent infinite, as well as headwinds from MIGS LCDs and the MDRP.

Management Comments

• Thomas Burns, Glaukos chairman and chief executive officer, stated that the record first quarter results reflect a strong start to the year and sustained growth acceleration driven by successful global execution of key strategic plans.
• Management believes that with the launch of iDose TR, they have the potential to reshape glaucoma management as we know it today.

Industry Context

Glaukos is operating in the ophthalmic pharmaceutical and medical technology sector, focusing on glaucoma, corneal disorders, and retinal diseases. The company's performance is influenced by factors such as regulatory approvals, reimbursement policies, and competition from other players in the MIGS and corneal health markets.

Comparison to Industry Standards

• It is difficult to make a direct comparison without knowing the specific growth rates and financial metrics of Glaukos' direct competitors in the MIGS and corneal health markets.
• However, the 25% year-over-year revenue growth suggests that Glaukos is performing well compared to the overall growth rate of the ophthalmic device market.
• Companies like Alcon, Johnson & Johnson Vision, and Bausch + Lomb are major players in the broader ophthalmology market, but their specific performance in the MIGS and corneal health segments would need to be analyzed for a more accurate comparison.

Stakeholder Impact

• Shareholders: Positive impact due to strong revenue growth and improved financial performance.
• Employees: Positive impact due to company growth and continued investment in R&D.
• Customers: Positive impact due to the availability of innovative therapies like iDose TR.
• Suppliers: Continued business relationships and potential for increased demand.
• Patients: Positive impact due to the development of new and improved treatments for eye diseases.

Next Steps

• Advance commercial launch activities in the U.S. for iDose TR and iStent infinite.
• Continue interventional glaucoma education efforts.
• Prepare for potential Epioxa FDA approval and commercial launch.
• Advance patient enrollment in PMA pivotal trial for iStent infinite in mild-to-moderate glaucoma patients.
• Advance patient enrollment in first-in-human Retina XR clinical development program for IVT multi-kinase inhibitor in wet AMD patients (GLK-401).
• Prepare to commence Phase 2 clinical trial for iLution Blepharitis by end of 2025.

Key Dates

Keywords

Glaukos, iDose TR, Glaucoma, Net Sales, Financial Results, Ophthalmology, Corneal Health, MIGS, Revenue, R&D